254 related articles for article (PubMed ID: 7620686)
1. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
2. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
[TBL] [Abstract][Full Text] [Related]
3. Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential.
Katz HI; Prawer SE; Watson MJ; Scull TA; Peets EA
Int J Dermatol; 1989 Jun; 28(5):342-4. PubMed ID: 2753592
[No Abstract] [Full Text] [Related]
4. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity.
Kecskés A; Heger-Mahn D; Kuhlmann RK; Lange L
J Am Acad Dermatol; 1993 Oct; 29(4):576-80. PubMed ID: 8408793
[TBL] [Abstract][Full Text] [Related]
5. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis.
Vernon HJ; Lane AT; Weston W
J Am Acad Dermatol; 1991 Apr; 24(4):603-7. PubMed ID: 2033138
[TBL] [Abstract][Full Text] [Related]
7. Topical glucocorticoids with improved benefit/risk ratio: do they exist?
Korting HC; Kerscher MJ; Schäfer-Korting M
J Am Acad Dermatol; 1992 Jul; 27(1):87-92. PubMed ID: 1619082
[TBL] [Abstract][Full Text] [Related]
8. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic index makes easier the choice of admissible substances. No fear concerning cortisone].
MMW Fortschr Med; 2003 Jul; 145(27-28):64. PubMed ID: 14587199
[No Abstract] [Full Text] [Related]
10. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
11. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
12. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.
Prakash A; Benfield P
Drugs; 1998 Jan; 55(1):145-63. PubMed ID: 9463794
[TBL] [Abstract][Full Text] [Related]
13. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
14. Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis.
Swinehart JM; Barkoff JR; Dvorkin D; Fisher G; Peets E
Int J Dermatol; 1989 Dec; 28(10):680-1. PubMed ID: 2687182
[No Abstract] [Full Text] [Related]
15. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
16. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate.
Mirshahpanah P; Döcke WD; Merbold U; Asadullah K; Röse L; Schäcke H; Zollner TM
Exp Dermatol; 2007 Sep; 16(9):753-61. PubMed ID: 17697148
[TBL] [Abstract][Full Text] [Related]
17. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.
Schäfer-Korting M; Korting HC; Kerscher MJ; Lenhard S
Clin Pharmacol Ther; 1993 Oct; 54(4):448-56. PubMed ID: 8222488
[TBL] [Abstract][Full Text] [Related]
18. Topical hydrocortisone 17-butyrate 21-propionate in the treatment of inflammatory skin diseases: pharmacological data, clinical efficacy, safety and calculation of the therapeutic index.
Fölster-Holst R; Abeck D; Torrelo A
Pharmazie; 2016 Mar; 71(3):115-21. PubMed ID: 27183704
[TBL] [Abstract][Full Text] [Related]
19. Sensitization studies with mometasone furoate, tixocortol pivalate, and budesonide in the guinea pig.
Bruze M; Bjorkner B; Dooms-Goossens A
Contact Dermatitis; 1996 Mar; 34(3):161-4. PubMed ID: 8833457
[TBL] [Abstract][Full Text] [Related]
20. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses.
Viglioglia P; Jones ML; Peets EA
J Int Med Res; 1990; 18(6):460-7. PubMed ID: 2292327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
